GSK Payments Probed
Talkin' 'Bout China Growth: Scandal, Red Tape No More?
By Randy Osborne
Wednesday, July 10, 2013
The regulatory system for drugs in China has improved since officials put the head of the country's FDA to death six years ago for accepting bribes, but the struggle is still uphill for drug developers inside the country and those trying to gain entry.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.